Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-β-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5' → 5')-N4- octadecyl-1-β-D-arabinofuranosylcytosine

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 6, 2000, Pages 311-319

  Horber, Daniel H ^a   Cattaneo Pangrazzi, Rosanna M C ^a   Von Ballmoos, Prisca ^a   Schott, Herbert ^b   Ludwig, Peter S ^b   Eriksson, Staffan ^c   Fichtner, Iduna ^d   Schwendener, Reto A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UPPSALA UNIVERSITY   (Sweden)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Apoptosis; Cytotoxicity; Drug resistance; N4 Alkyl AraC derivatives; NOAC AraC dimer

Indexed keywords

BOVINE SERUM ALBUMIN; BROXURIDINE; CAMPTOTHECIN; CASPASE 3; CYTARABINE 5' STEARYLPHOSPHATE; CYTARABINE DERIVATIVE; DEOXYCYTIDINE KINASE; DINUCLEOSIDE PHOSPHATE; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; FLUORESCEIN; GLYCOPROTEIN P; LIPOSOME; PHOSPHODIESTERASE; POLYSORBATE 20; PROPIDIUM IODIDE; RIBONUCLEASE A; VERAPAMIL;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL STRAIN HL 60; CELL STRAIN KB; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIPOPHILICITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR CELL LINE; TUMOR XENOGRAFT;

EID: 0034040603     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050349     Document Type: Article

References (25)

1. Cavazzana M, Calvo F, Facchin P, Barreau P, Geny B, Dal Cl, Dresch C (1988) Use of liquid culture and cell cycle analysis to compare drug damage following in vitro treatment of normal human bone marrow cells with adriamycin, arabinosylcytosine, and etoposide. Exp Hematol 16: 876-883
2. Fichtner I, Goan S-R, Becker M, Baldy C, Borgmann A, von Stackelberg A, Henze H (1999) Transplantation of human haematopoietic or leukaemic cells into SCID and NOD/SCID mice. In: Fiebig HH, Burger AM (eds) Relevance of tumor models for anticancer drug development. Contrib Oncol 54: 207-217
3. Fram RJ, Kufe DW (1985) Effect of 1-β-D-arabinofuranosylcytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts. Biochem Pharmacol 34: 2557-2560
4. Gong J, Li X, Darzynkiewicz Z (1993) Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin. J Cell Physiol 157: 263-270
5. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 71: 957-962
6. 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 36: 483-492
7. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a new lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 72: 1067-1073
8. 3H]vinblastine transport by isolated vesicles. Biochim Biophys Acta 1061: 106-110
9. Karlsson A, Johansson M, Eriksson S (1994) Cloning and expression of mouse deoxycytidine kinase. J Biol Chem 269: 24374-24378
10. Kolla SS, Studzinski GP (1994) Constitutive DNA binding of the low mobility forms of the AP-1 and SP-1 transcription factors in HL60 cells resistant to 1-β-D-arabinofuranosylcytosine. Cancer Res 54: 1418-1421
11. 4-octadecyl-1-β-D-arabinofuranosylcytosine, a new anticancer drug. J Pharmacol Exp Ther 282: 1572-1580
12. 4-octadecyl-1-β-D-arabinofuranosylcytosine in mice. Drug Metab Dispos 27: 342-350
13. Plunkett W, Gandhi V (1993) Cellular pharmacodynamics of anticancer drugs. Semin Oncol 20: 50-63
14. Preisler HD, Gopal V, Banavali SD, Finke D, Bokari SA (1992) Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. Cancer Res 52: 4090-4095
15. 4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC) in plasma and whole blood after intravenous and oral application in mice. J Pharm Pharmacol 49: 1076-1081
16. Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, Schott H, Schwendener RA (1986) Treatment of murine L1210 leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37: 149-154
17. Schott H, Häussler MP, Schwendener RA (1994) Synthese von 4-Alkylcytosin-nukleosiden und deren cytotstatische Wirkung im L1210 Leukämiemodell der Maus. Liebigs Ann Chem 465-470
18. 4-octadecylcyditine: a new amphiphilic dinucleoside phosphate. Liebigs Ann Chem 413-417
19. Schott H, Ludwig PS, Immelmann A, Schwendener RA (1999) Synthesis and in vitro anti-HIV activities of amphiphilic heterodinucleoside phosphate derivatives containing the 2′, 3′-dinucleosides ddC, AZT and ddI. Eur J Med Chem 34: 343-352
20. 4-hexadecyl-1-β-D-arabinofuranosyl cytosine. Int J Cancer 51: 466-469
21. Schwendener RA, Schott H (1996) Lipophilic 1-β-D-arabinofuranosylcytosine (Ara-C) derivatives in liposomal formulations for the oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J Cancer Res Clin Oncol 122: 723-726
22. 4-oleyl-cytosine arabinoside. In: Lopez-Berenstein G, Fidler IJ (eds) Liposomes in the therapy of infectious disease and cancer. Liss, New York, pp 95-105
23. 4-octadecyl-1-β-D-arabinofuranosylcytosine in liposomal preparations. J Liposome Res 5: 27-47
24. 4-octadecyl-ara-C, NOAC. Drugs Future 20: 11-15
25. 4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine (ara-C). J Cancer Res Clin Oncol 122: 102-108